Human HepaRG cells can be cultured in hanging-drop plates for cytochrome P450 induction and function assays

Drug Metabolism Letters

Volumn 9, Issue 1, 2015, Pages 3-7

  Murayama, Norie ^a   Usui, Takashi ^b   Slawny, Nicky ^c   Chesné, Christophe ^d   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b Nikkyo Technos Co Ltd   (Japan)

^c 3D Biomatrix Inc   (United States)

^d Société Biopredic International   (France)

Author keywords

CYP1A2; CYP2B6; CYP3A4; Drug interaction; Hanging drop; HepaRG; Human hepatocytes

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; MESSENGER RNA; MIDAZOLAM; OMEPRAZOLE; PHENOBARBITAL; RIFAMPICIN; CYP1A2 PROTEIN, HUMAN; CYP2B6 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 INDUCER;

ARTICLE; CATALYSIS; CELL CULTURE; CRYOPRESERVATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INDUCTION; FUNCTION TEST; GLUCURONIDATION; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER CELL; METHODOLOGY; PRIORITY JOURNAL; BIOSYNTHESIS; CELL CULTURE TECHNIQUE; DRUG EFFECTS; DRUG INTERACTION; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; HEPG2 CELL LINE; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR;

CELL CULTURE TECHNIQUES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2B6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME INDUCERS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; HEP G2 CELLS; HEPATOCYTES; HUMANS; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 84934761586     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872312809666150119104806     Document Type: Article

References (10)

1. Hewitt, N. J.; Lechon, M. J.; Houston, J. B.; Hallifax, D.; Brown, H. S.; Maurel, P.; Kenna, J. G.; Gustavsson, L.; Lohmann, C.; Skonberg, C.; Guillouzo, A.; Tuschl, G.; Li, A. P.; Lecluyse, E.; Groothuis, G. M.; Hengstler, J. G. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev., 2007, 39, 159-234.
2. Turpeinen, M.; Tolonen, A.; Chesne, C.; Guillouzo, A.; Uusitalo, J.; Pelkonen, O. Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol. in vitro, 2009, 23, 748-753.
3. Yajima, K.; Uno, Y.; Murayama, N.; Uehara, S.; Shimizu, M.; Nakamura, C.; Iwasaki, K.; Utoh, M.; Yamazaki, H. Evaluation of 23 lots of commercially available cryopreserved hepatocytes for induction assays of human cytochromes P450. Drug Metab. Dispos., 2014, 42, 867-871.
4. Antherieu, S.; Chesne, C.; Li, R.; Guguen-Guillouzo, C.; Guillouzo, A. Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol. in vitro, 2012, 26, 1278-1285.
5. Antherieu, S.; Chesne, C.; Li, R.; Camus, S.; Lahoz, A.; Picazo, L.; Turpeinen, M.; Tolonen, A.; Uusitalo, J.; Guguen-Guillouzo, C.; Guillouzo, A. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab. Dispos., 2010, 38, 516-525.
6. Nakamura, K.; Mizutani, R.; Sanbe, A.; Enosawa, S.; Kasahara, M.; Nakagawa, A.; Ejiri, Y.; Murayama, N.; Miyamoto, Y.; Torii, T.; Kusakawa, S.; Yamauchi, J.; Fukuda, M.; Yamazaki, H.; Tanoue, A. Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system. J. Biosci. Bioeng., 2011, 111, 78-84.
7. Murayama, N.; van Beuningen, R.; Suemizu, H.; Guguen-Guillouzo, C.; Shibata, N.; Yajima, K.; Utoh, M.; Shimizu, M.; Chesne, C.; Nakamura, M.; Guengerich, F. P.; Houtman, R.; Yamazaki, H. Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of pregnane X receptor. Chem. Res. Toxicol., 2014, 27, 304-308.
8. Gunness, P.; Mueller, D.; Shevchenko, V.; Heinzle, E.; Ingelman-Sundberg, M.; Noor, F. 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. Toxicol. Sci., 2013, 133, 67-78.
9. Jetten, M. J.; Kleinjans, J. C.; Claessen, S. M.; Chesne, C.; van Delft, J. H. Baseline and genotoxic compound induced gene expression profiles in HepG2 and HepaRG compared to primary human hepatocytes. Toxicol. in vitro, 2013, 27, 2031-2040.
10. Klein, S.; Mueller, D.; Schevchenko, V.; Noor, F. Long-term maintenance of HepaRG cells in serum-free conditions and application in a repeated dose study. J Appl. Toxicol., 2014, 34, 1078-1086.